FINWIRES · TerminalLIVE
FINWIRES

$IONS

24 stories mentioning IONSUpdated 9d ago

Every FINWIRES story that references IONS, newest first.

What are analysts saying about IONS?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on IONS?

Wire

Ionis Pharmaceuticals' Zanvastro Approval Sets Path for Independent Neurology Business, Oppenheimer Says

Ionis Pharmaceuticals (IONS) has established its first independently commercialized neurology asset with the approval of Zanvastro for Alexander disease, Oppenheimer said in a Friday note.The US Food and Drug Administration approval creates an infrastructure, a clinical network and a commercial foundation that can be leveraged for future central nervous system, or CNS, targeted drug launches, the firm said.Oppenheimer said the approval also provides further validation of the company's CNS antisense drug development capabilities, while noting it provides favorable read-through for obudanersen, whose phase 3 study recently completed enrollment.Oppenheimer maintained its outperform rating on Ionis Pharmaceuticals and $85 price target.Price: $58.28, Change: $+0.15, Percent Change: +0.26%

$IONS
Sectors

Sector Update: Healthcare Stocks Mixed Pre-Bell Friday

Healthcare stocks were mixed pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.2% and the iShares Biotechnology ETF (IBB) 0.1% higher.Novo Nordisk's (NVO) charitable foundation and its Quantum Foundry Copenhagen company are planning to set up a new 5,300 square meter quantum chip production facility in Copenhagen, the organizations said. Shares of Novo Nordisk were down more than 2% premarket.Bristol Myers Squibb (BMY) told regulators, researchers and patient groups in early June that it had paused trials of its CAR-T treatment zola-cel in autoimmune disorders over potentially life-threatening side effects, The Wall Street Journal reported. Bristol Myers Squibb stock was down 1% pre-bell.Ionis Pharmaceuticals (IONS) shares were 0.8% higher after the company said the US Food and Drug Administration approved zanvastrotm, or zilganersen, to treat Alexander disease in pediatric and adult patients.

$BMY$IBB$IONS$NVO$XLV
Insider Trading

Ionis Pharmaceuticals Insider Bought Shares Worth $1,058,700, According to a Recent SEC Filing

Michael R Hayden, Director, on July 30, 2026, executed a purchase for 20,000 shares in Ionis Pharmaceuticals (IONS) for $1,058,700. Following the Form 4 filing with the SEC, Hayden has control over a total of 78,298 common shares of the company, with 54,298 shares held directly and 24,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/874015/000087401526000254/xslF345X05/edgardoc.xml

$IONS
Wire

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday.Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) remain its top picks.Bank of America raised its price targets on AbbVie to $276 from $234, Johnson & Johnson (JNJ) to $263 from $254 and Eli Lilly to $1,334 from $1,251.The analysts lowered targets on Bristol Myers Squibb (BMY) to $66 from $67, Pfizer (PFE) to $26 from $27 and United Therapeutics (UTHR) to $613 from $620.Price: $123.45, Change: $-1.63, Percent Change: -1.30%

$ABBV$BMY$IONS$JAZZ$JNJ$LLY$MRK$PFE$UTHR
Insider Trading

Ionis Pharmaceuticals Insider Sold Shares Worth $1,744,623, According to a Recent SEC Filing

C Frank Bennett, Executive Vice President, Chief Scientific Officer, on July 07, 2026, sold 20,536 shares in Ionis Pharmaceuticals (IONS) for $1,744,623. Following the Form 4 filing with the SEC, Bennett has control over a total of 75,018 common shares of the company, with 75,018 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/874015/000087401526000239/xslF345X05/edgardoc.xml

$IONS
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) increased 0.3%.In corporate news, AstraZeneca (AZN) and its partner Ionis Pharmaceuticals (IONS) said Thursday that a phase 3 trial for eplontersen in people with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint. AstraZeneca shares fell 5%, and Ionis tumbled 23%.Qiagen (QGEN) is attracting early takeover interest from private equity firms, including EQT AB, Advent and KKR (KKR), with some potential bidders considering offers of at least $50 per share, Bloomberg reported. Qiagen shares jumped 10%.Fate Therapeutics (FATE) shares rose past 5% after the US Food and Drug Administration approved the company's investigational new drug application for FT839, a product candidate to treat autoimmune diseases.MetaVia (MTVA) shares climbed 11% after it said Thursday that all active patients in part 3 of its phase 1 trial for obesity drug candidate DA-1726 have completed dose titration and reached their highest planned doses of 48 mg and 64 mg.

$AZN$FATE$IONS$MTVA$QGEN
Wire

Top Midday Decliners

Aimei Health Technology (AFJK) terminated its merger deal with United Hydrogen Group, effective immediately, as the companies failed to complete the transaction within the agreed timeframe, according to a statement Wednesday.Shares of Aimei sank 49% as intraday trading volume jumped to over 165,000 from a daily average of about 10,000.AstraZeneca (AZN) and its partner Ionis Pharmaceuticals (IONS) said Thursday that a phase 3 trial for eplontersen in people with transthyretin-mediated amyloid cardiomyopathy failed to meet the primary efficacy endpoint.Shares of Ionis sank 24% as intraday trading volume soared to about 14.5 million from a daily average of roughly 1.89 million.Rackspace Technology (RXT) said Thursday that it expects a wider Q2 adjusted loss from a year earlier and also lowered its full-year 2026 outlook.Shares plunged 29% as intraday trading volume surged to over 40.0 million from the stock's daily average of about 24.1 million.Price: $13.45, Change: $-13.24, Percent Change: -49.61%

$AFJK$AZN$IONS$RXT
Sectors

Sector Update: Healthcare Stocks Decline in Afternoon Trading

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, AstraZeneca (AZN) and its partner Ionis Pharmaceuticals (IONS) said Thursday that a phase 3 trial for eplontersen in people with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint. AstraZeneca shares fell 5.4%, and Ionis tumbled 24%.Qiagen (QGEN) is attracting early takeover interest from private equity firms, including EQT AB, Advent and KKR (KKR), with some potential bidders considering offers of at least $50 per share, Bloomberg reported. Qiagen shares jumped past 10%.MetaVia (MTVA) shares rose 9% after it said Thursday that all active patients in part 3 of its phase 1 trial for obesity drug candidate DA-1726 have completed dose titration and reached their highest planned doses of 48 mg and 64 mg.

$AZN$IONS$MTVA$QGEN
Sectors

Sector Update: Healthcare

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, AstraZeneca (AZN) and its partner Ionis Pharmaceuticals (IONS) said Thursday that a phase 3 trial for eplontersen in people with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint. AstraZeneca shares fell 5%, and Ionis tumbled 23%.

$AZN$IONS
Wire

Needham Adjusts Ionis Pharmaceuticals Price Target to $86 From $105, Maintains Buy Rating

Needham Adjusts Ionis Pharmaceuticals Price Target to $86 From $105, Maintains Buy Rating

$IONS
Wire

TD Cowen Adjusts Ionis Pharmaceuticals Price Target to $94 From $108, Maintains Buy Rating

TD Cowen Adjusts Ionis Pharmaceuticals Price Target to $94 From $108, Maintains Buy Rating

$IONS
Sectors

Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday

Healthcare stocks were mixed pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) up 0.6%.Ionis Pharmaceuticals (IONS) and partner AstraZeneca (AZN) said a phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM, failed to meet the primary efficacy endpoint. Shares of Astrazeneca were down more than 7% and Ionis Pharmaceuticals stock fell past 19% premarket.Greenwich LifeSciences (GLSI) shares were up more than 7% after the company said the European Medicines Agency cleared the use of commercially manufactured GP2 in a phase 3 trial evaluating GLSI-100 to prevent breast cancer recurrence in Europe.Natera (NTRA) said its Signatera molecular residual disease test received European Union In Vitro Diagnostic Regulation Class C certification for use across multiple solid tumor types. Shares of Natera were down more than 1% pre-bell.

$AZN$GLSI$IBB$IONS$NTRA$XLV
Commodities

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday as Chip Stocks Rebound Despite US-Iran Tensions

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3%, and the actively traded Invesco QQQ Trust (QQQ) advanced 0.9% in Thursday's premarket activity, as investors returned to chip stocks while monitoring escalating tensions between Washington and Tehran.US stock futures were mixed, with S&P 500 Index futures up 0.2%, Dow Jones Industrial Average futures slipping 0.1%, and Nasdaq futures gaining 0.6% before the start of regular trading.US initial jobless claims fell to a level of 215,000 in the week ended July 4 from an upwardly revised 217,000 level in the previous week, compared with expectations for a level of 217,000 in a survey of analysts compiled by Bloomberg.The existing home sales data will be released at 10:00 am ET, followed by natural gas stocks data at 10:30 am ET.New York Federal Reserve President John Williams and Dallas Fed President Lorie Logan are slated to speak on Thursday.In premarket action, bitcoin was up by 0.8%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.8% higher, Ether ETF (EETH) advanced 0.1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.4%, while the Vanguard Industrials Index Fund (VIS) was up 0.3% and the iShares US Industrials ETF (IYJ) was flat.FuelCell Energy (FCEL) stock was up more than x% before the opening bell after the company and Siemens agreed to collaborate on fuel cell-based power generation.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated by 0.3%, the Vanguard Health Care Index Fund (VHT) was 0.9% higher, while the iShares US Healthcare ETF (IYH) gained by 0.2%. The iShares Biotechnology ETF (IBB) was up 0.8%.AstraZeneca (AZN) stock was down more than 8% premarket, and Ionis Pharmaceuticals (IONS) fell over 20% after the partners said a phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM, failed to meet the primary efficacy endpoint.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced 1.8%, the iShares US Technology ETF (IYW) was 1.4% higher, and the iShares Expanded Tech Sector ETF (IGM) was up 1.5%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 3.9%, while the iShares Semiconductor ETF (SOXX) rose 4.9%.Applied Materials (AMAT) shares were up more than 4% in premarket activity after Nikkei Asia reported, citing CEO Gary Dickerson, that the company is seeing stronger long-term visibility into semiconductor equipment demand as major chipmakers share production plans extending well beyond 2027.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.4%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) retreated by 1.1%, and the iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.3%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was 0.3% lower.Levi Strauss (LEVI) shares were down nearly 4% early Thursday after the company's new full-year earnings outlook fell short of analyst estimates even as its fiscal Q2 results topped views.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.3%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.4% lower.Broadridge Financial Solutions (BR) shares traded up 1% in early hours activity after the company said that Centralised Raiffeisen International Services & Payments, the shared services center of Raiffeisen Bank International, has upgraded to its cloud-based BRx Match reconciliation platform.EnergyThe iShares US Energy ETF (IYE) gained 1.3%, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 0.3%.Sempra (SRE) stock was down more than 1% before market open. The company said Wednesday that its Sempra Infrastructure unit shipped the first liquefied natural gas cargo from the ECA LNG Phase 1 project in Mexico, marking a milestone ahead of the facility's expected commercial operations later this summer.CommoditiesFront-month US West Texas Intermediate crude oil advanced by 0.4% to $73.82 per barrel on the New York Mercantile Exchange. Natural gas was down by 0.8% to $3.19 per 1 million British Thermal Units. The United States Oil Fund (USO) retreated by 0.4%, while the United States Natural Gas Fund (UNG) was 0.8% lower.Gold futures for July rose 1% to $4,122.20 an ounce on the Comex. Silver futures advanced by 1.9% to $59.67 an ounce. SPDR Gold Shares (GLD) increased 0.8%, and the iShares Silver Trust (SLV) was 1.8% higher.

Dow JonesNasdaq CompositeS&P 500$AMAT$AZN$BETH$BITO$BR$EEM$EETH$EXI$FAS$FAZ$FCEL$GLD$IBB$IGM$IGV$IONS$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$LEVI$PMR$QQQ$RTH$SLV$SOXX$SPY$SRE$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Asia Markets

Update: US Equity Futures Edge Higher Pre-Bell Amid Re-Escalation of Middle East Hostilities

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were higher pre-bell Thursday as traders observed the recent rise in hostilities between the US and Iran, which threatened to derail peace talks between the two nations.Dow Jones Industrial Average futures were flat, S&P 500 futures were up 0.3%, and Nasdaq futures were 0.9% higher.In a post on X, US Central Command said it completed a second round of strikes, hitting 90 more Iranian military targets. The US military had struck 80 Iranian targets the day before in response to Iran's attacks on three commercial ships transiting the Strait of Hormuz.President Donald Trump told reporters that Iran had reached out and "badly" wanted to make a deal to halt the escalating hostilities in the Middle East. Trump said he does not know if the two nations are returning to an all-out conflict, but added that the US would win "very quickly" if the war resumed.Traders also digested the latest round of earnings, with PepsiCo (PEP) posting higher fiscal Q2 core earnings and revenue.Oil prices were higher, with front-month global benchmark North Sea Brent crude up 0.9% at $78.71 per barrel and US West Texas Intermediate crude 0.8% higher at $74.09 per barrel.Initial jobless claims dropped to 215,000 in the week ended July 4 from 217,000 in the previous week, compared with expectations for no change in a survey compiled by Bloomberg.The existing home sales report, scheduled for release at 10 am ET, is expected to show an increase of 1.0% for June after a gain of 3.2% in the prior month.New York Federal Reserve President John Williams and Dallas Fed President Lorie Logan are slated to speak on Thursday.In other world markets, Japan's Nikkei closed 1.4% higher, Hong Kong's Hang Seng ended 0.7% lower, and China's Shanghai Composite finished 1.7% higher. Meanwhile, the UK's FTSE 100 was down 0.6%, and Germany's DAX index was 0.3% higher in Europe's early afternoon session.In equities, Costco Wholesale (COST) shares fell 1.7% after the company posted June net sales of $29.2 billion, up almost 11% from $26.4 billion a year earlier, and maintained its quarterly dividend at $1.47 a share.PepsiCo stock was down 2.5% after the company reported its fiscal Q2 financial results.Ionis Pharmaceuticals (IONS) and partner AstraZeneca (AZN) shares fell 19% and 7.8%, respectively, after they said a phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy failed to meet the primary efficacy endpoint.On the winning side, Micron Technology (MU), AMD (AMD), and Intel (INTC) stocks rose as part of a broader rally in the semiconductor sector. Micron shares climbed 6.4%, AMD stock was up 4%, and Intel shares were 5.3% higher.Applied Materials (AMAT) shares rose 7.1% after a Nikkei Asia report citing CEO Gary Dickerson as saying that the company is seeing stronger long-term visibility into semiconductor equipment demand as major chipmakers share production plans extending well beyond 2027.

Dow JonesNasdaq CompositeS&P 500$AMAT$AMD$AZN$COST$INTC$IONS$MU$PEP
Insider Trading

Ionis Pharmaceuticals Insider Sold Shares Worth $2,107,196, According to a Recent SEC Filing

Eugene Schneider, Executive Vice President, Chief Clinical Development Officer, on June 26, 2026, sold 26,000 shares in Ionis Pharmaceuticals (IONS) for $2,107,196. Following the Form 4 filing with the SEC, Schneider has control over a total of 77,114 common shares of the company, with 77,114 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/874015/000087401526000216/xslF345X05/edgardoc.xml

$IONS
Wire

Ionis' Tryngolza Receives FDA Approval to Treat Acute Pancreatitis in Severe Hypertriglyceridemia Patients

Ionis Pharmaceuticals' (IONS) Tryngolza, used with diet, received approval from the US Food and Drug Administration to reduce triglycerides and the risk of acute pancreatitis in adult patients with severe hypertriglyceridemia, the agency said Wednesday.Tryngolza received Priority Review and Breakthrough Therapy designations from the FDA for this indication, and the approval was granted to Ionis, according to a statement. Severe hypertriglyceridemia is a serious condition with fasting triglyceride levels of at least 500 mg/dL.The approval is founded on efficacy and safety data from two trials in a total of 1,061 patients, which showcased that the rate of acute pancreatitis was reduced compared with the placebo group, according to the FDA.Price: $76.79, Change: $+0.80, Percent Change: +1.05%

$IONS
Insider Trading

Ionis Pharmaceuticals Insider Sold Shares Worth $587,920, According to a Recent SEC Filing

Spencer R Berthelsen, Director, on June 15, 2026, sold 8,000 shares in Ionis Pharmaceuticals (IONS) for $587,920. Following the Form 4 filing with the SEC, Berthelsen has control over a total of 156,083 common shares of the company, with 156,013 shares held directly and 70 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/874015/000087401526000207/xslF345X05/edgardoc.xml

$IONS
Insider Trading

Ionis Pharmaceuticals Insider Sold Shares Worth $4,466,428, According to a Recent SEC Filing

Holly B. Kordasiewicz, Executive Vice President, Chief Development Officer, on June 12, 2026, sold 60,846 shares in Ionis Pharmaceuticals (IONS) for $4,466,428. Following the Form 4 filing with the SEC, Kordasiewicz has control over a total of 22,458 common shares of the company, with 22,458 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/874015/000087401526000208/xslF345X05/edgardoc.xml

$IONS
Insider Trading

Ionis Pharmaceuticals Insider Sold Shares Worth $605,360, According to a Recent SEC Filing

Spencer R Berthelsen, Director, on June 01, 2026, sold 8,000 shares in Ionis Pharmaceuticals (IONS) for $605,360. Following the Form 4 filing with the SEC, Berthelsen has control over a total of 156,083 common shares of the company, with 156,013 shares held directly and 70 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/874015/000087401526000188/xslF345X05/edgardoc.xml

$IONS
Research

Research Alert: CFRA Raises Rating On Shares Of Ionis Pharmaceuticals, Inc. To Buy From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to $92 from $86 based on our discounted cash flow analysis. We widen our 2026 loss per share forecast to -$2.62 from -$2.42 and our 2027 loss per share estimate to -$0.66 from -$0.35. IONS demonstrated significant positive momentum, reporting a very strong Q1 and significantly beating revenue and LPS estimates. Total Q1 revenue surged to $246M (+87% Y/Y) driven by robust operational execution and accelerating demand for Ionis' key commercial products. TRYNGOLZA (Olezarsen) sales rose by a record 350% Y/Y and DAWNZERA sales increased by 125% Q/Q in Q1. The upcoming launch of Olezarsen in severe hypertriglyceridemia (sHTG) indication targets a large addressable market of over 3 million patients and positions the treatment to be Ionis' first wholly-owned blockbuster medicine, in our view. We think the pipeline progress and successful operational execution position Ionis well for substantial near-term growth, reinforcing its evolution into a fully integrated commercial biotech company.

$IONS

Showing 1-20 of 24

Track with the FINWIRES app suite

FolioX
FolioX
Track IONS in your portfolio
WheelAI
WheelAI
Analyze IONS options with the wheel strategy
StockInsider
StockInsider
See market sentiment on IONS